Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial.
Ezra E W CohenLisle NabellDeborah J WongTerry A DayGregory A DanielsMohammed MilhemSanjeev DevaMichael B JamesonOrlando Guntinas-LichiusMohammed AlmubarakMatthew StrotherEric D WhitmanMichael ChisamoreCynthia ObiozorTeresa BagulhoJose Gomez-RomoCristiana GuiducciRobert JanssenErick GamelinAlain Patrick AlgaziPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
SD-101 combined with pembrolizumab induced objective responses, especially in HPV+ tumors, which were frequently associated with increased intratumoral inflammation and effector immune cell activity.